In the last trading session, 1.41 million Akero Therapeutics Inc (NASDAQ:AKRO) shares changed hands as the company’s beta touched -0.11. With the company’s per share price at $42.17 changed hands at $1.17 or 2.85% during last session, the market valuation stood at $3.36B. AKRO’s last price was a discount, traded about -38.49% off its 52-week high of $58.40. The share price had its 52-week low at $17.86, which suggests the last value was 57.65% up since then. When we look at Akero Therapeutics Inc’s average trading volume, we note the 10-day average is 1.02 million shares, with the 3-month average coming to 1.44 million.
Analysts gave the Akero Therapeutics Inc (AKRO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKRO as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Akero Therapeutics Inc’s EPS for the current quarter is expected to be -0.99.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Instantly AKRO was in green as seen at the end of in last trading. With action 11.95%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 51.58%, with the 5-day performance at 11.95% in the green. However, in the 30-day time frame, Akero Therapeutics Inc (NASDAQ:AKRO) is -3.24% down. Looking at the short shares, we see there were 6.31 million shares sold at short interest cover period of 5.1 days.
The consensus price target for the stock as assigned by Wall Street analysts is 45, meaning bulls need an upside of 6.29% from its current market value. According to analyst projections, AKRO’s forecast low is 38 with 56 as the target high. To hit the forecast high, the stock’s price needs a -32.8% plunge from its current level, while the stock would need to tank 9.89% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -5.28%. The 2025 estimates are for Akero Therapeutics Inc earnings to decrease by -14.49%, but the outlook for the next 5-year period is at -8.19% per year.
AKRO Dividends
Akero Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-27.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.30% of Akero Therapeutics Inc shares while 94.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 96.43%. There are 94.21% institutions holding the Akero Therapeutics Inc stock share, with JANUS HENDERSON GROUP PLC the top institutional holder. As of 2024-06-30, the company held 9.9425% of the shares, roughly 6.88 million AKRO shares worth $161.28 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.0778% or 5.59 million shares worth $131.06 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Russell 2000 ETF . With 4.07 shares estimated at $171.62 million under it, the former controlled 5.11% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.46% of the shares, roughly 1.96 shares worth around $82.74 million.
